Literature DB >> 4246888

Limiting factors of the anaphylatoxin forming system in plasma from different species.

R Brandt, D Schwoerer, W Vogt.   

Abstract

Mesh:

Substances:

Year:  1970        PMID: 4246888     DOI: 10.1007/bf00997116

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmakol


× No keyword cloud information.
  8 in total

1.  Preparation and some properties of anaphylatoxin from hog serum.

Authors:  W Vogt
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

2.  Functional identity of anaphylatoxin preparations obtained from different sources and by different activation procedures. 1. Pharmacological experiments.

Authors:  I Kleine; B Poppe; W Vogt
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

3.  Formation of anaphylatoxin in human serum.

Authors:  W Vogt; G Bodammer; E Lufft; G Schmidt
Journal:  Experientia       Date:  1969

4.  [Separation of an anaphylatoxin-forming principle from other venom components in cobra venom].

Authors:  W Vogt; G Schmidt
Journal:  Experientia       Date:  1964-04-15

5.  Separation, purification and properties of two proteins from rat serum which are essential for anaphylatoxin formation.

Authors:  W Vogt; G Schmidt
Journal:  Biochem Pharmacol       Date:  1967-10       Impact factor: 5.858

6.  Formation of anaphylatoxin in rat plasma, a specific enzymic process.

Authors:  W Vogt; G Schmidt
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

7.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

8.  The properdin system and immunity. III. The zymosan assay of properdin.

Authors:  L PILLEMER; L BLUM; I H LEPOW; L WURZ; E W TODD
Journal:  J Exp Med       Date:  1956-01-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.